阿哌沙班预防透析血管通路血栓切除术后再血栓的随机对照试验
多中心随机对照试验纳入186例成功行血管内血栓切除术的血液透析患者,随机分为标准治疗组和标准治疗加阿哌沙班2.5mg每日两次组,治疗3个月。阿哌沙班组3个月通路血栓复发率显著低于对照组(24.0% vs 40.8%;HR 0.52,95%CI 0.31-0.88),主要通畅失败率也显著改善(32.2% vs 49.5%,HR 0.57,95%CI 0.36-0.91)。两组死亡和大出血发生率相当,但阿哌沙班组轻微出血发生率显著更高(22.6% vs 7.5%)。
要点
- 阿哌沙班降低透析通路血栓切除术后3个月再血栓风险(HR 0.52)。
- 阿哌沙班改善主要通畅失败率(HR 0.57)。
- 轻微出血增加(22.6% vs 7.5%),但大出血和死亡无差异。
核心结论
- 阿哌沙班有效降低血液透析血管通路血栓切除术后再发血栓风险,净临床获益支持其使用。
研究设计与样本
- 多中心随机对照试验(NCT04489849),纳入186例48小时内成功行血管内血栓切除术的血液透析患者,开放标签给药,终点独立裁定。
主要发现
- 阿哌沙班组3个月通路血栓发生率24.0%,对照组40.8%(HR 0.52,95%CI 0.31-0.88)。
- 阿哌沙班组主要通畅失败率32.2%,对照组49.5%(HR 0.57,95%CI 0.36-0.91)。
- 阿哌沙班组轻微出血发生率22.6%,对照组7.5%,两组死亡和大出血发生率相当。
- 亚组分析显示不同通路类型、抗血小板药物使用、合并症严重程度或血栓史未见交互作用。
关键数值与推荐
- 阿哌沙班剂量为2.5 mg每日两次,疗程3个月。
- 主要疗效终点为血栓切除术后3个月内再发通路血栓。
临床怎么用
- 对于血液透析血管通路血栓切除术后患者,可考虑加用阿哌沙班2.5 mg每日两次预防再血栓,但需监测轻微出血。
局限性
- 开放标签设计可能引入偏倚,终点采用独立裁定以部分缓解。
- 样本量186例,随访3个月,长期疗效和安全性未评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Dialysis vascular access thrombosis poses a substantial challenge for individuals undergoing hemodialysis. The efficacy and safety of apixaban, a direct oral coagulation factor Xa inhibitor, in preventing recurrent access thrombosis have yet to be explored. Here, a multicenter randomized control study (NCT04489849) enrolled hemodialysis patients to evaluate this who underwent successful endovascular thrombectomy within 48 hours. Participants were assigned to standard care or standard care plus apixaban, 2.5 mg twice daily for three months. The trial design involved open-label administration, with independent adjudication of endpoints. The primary efficacy endpoint was recurrent access thrombosis within three months after thrombectomy. A total of 186 patients with well-balanced baseline characteristics were enrolled, 93 randomized to the apixaban group and 93 to the control group. The apixaban group demonstrated a significantly lower rate of access thrombosis at three months than the control group (24.0% vs. 40.8%; hazard ratio, 0.52 [95% confidence interval 0.31-0.88]), along with a significantly better primary patency failure rate (32.2% vs. 49.5%, 0.57 [0.36-0.91]). Safety outcomes showed comparable death rates and major bleeding incidents but significantly higher incidence of minor bleeding in the apixaban group (22.6% vs. 7.5%). The effect of apixaban did not show interaction in subgroups of different access types, antiplatelet usage, severity of comorbidities, or history of thrombosis. Thus, apixaban effectively reduced the risk of recurrent thrombosis in hemodialysis vascular access post-thrombectomy. Despite a minor increase in bleeding adverse effects, the net clinical benefit favors the use of apixaban in this context.
引用
- Ko TY, Wu CC, Hsieh MY, et al. A randomized controlled trial evaluated the efficacy and safety of apixaban for prevention of recurrent thrombosis after thrombectomy of hemodialysis vascular access. Kidney Int. 2024. PMID: 39551132. doi:10.1016/j.kint.2024.10.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。